JMB-HEADER RAS-JOURNALS EIMB Pleiades Publishing

RUS

             

ENG

YearIMPACT-FACTOR
2024  1,200
2023  1,500
2022  1,200
2021  1,540
2020  1,374
2019  1,023
2018  0,932
2017  0,977
2016  0,799
2015  0,662
2014  0,740
2013  0,739
2012  0,637
2011  0,658
2010  0,654
2009  0,570
2008  0,849
2007  0,805
2006  0,330
2005  0,435
2004  0,623
2003  0,567
2002  0,641
2001  0,490
2000  0,477
1999  0,762
1998  0,785
1997  0,507
1996  0,518
1995  0,502
Vol 59(2025) N 2 p. 214-223; DOI 10.1134/S0026893324700845 Full Text

O.V. Orlova1*, D.V. Glazkova1, O.N. Sidorova1, F.A. Urusov1,2, G.A. Shipulin1, E.V. Bogoslovskaya1

Dynamics of Transgene Expression in the MVA Vaccine Vector under the Control of the p11, p13.5, pLEO160, p7.5, and mH5 Promoters and Independence of the Transgene Expression Level from the Insertion Locus

1Center for Strategic Planning and Management of Biomedical Health Risks, Federal Medical Biological Agency, Moscow, 119121 Russia
2Izmerov Research Institute of Occupational Health, Moscow, 119121 Russia

*oorlova@cspmz.ru
Received - 2024-06-14; Revised - 2024-09-16; Accepted - 2024-09-30

The modified vaccinia virus Ankara (MVA), characterized by high immunogenicity and proven safety, is considered a promising vector for vaccine development. An undeniable advantage of the MVA vector is its high capacity and the ability to incorporate several transgenes into different loci of the viral genome, enabling the creation of multivalent vaccines that encode multiple antigens simultaneously. This study examined the expression of a transgene encoding influenza virus protein epitopes after its integration into five loci of the MVA genome. The results demonstrated that the level of transgene expression is independent of the integration locus. Additionally, the dynamics of the expression of a reporter gene encoding the Enhanced Green Fluorescent Protein (EGFP) were determined under the control of the vaccinia virus promoters p11, p13.5, pLEO160, p7.5, and mH5 upon insertion of the expression cassette into the F13L gene locus of MVA. The highest expression level, though with a delayed onset of protein synthesis, was achieved with the late promoter p11. Using the p13.5 promoter resulted in earlier synthesis of EGFP in cells and higher gene expression level compared to the promoters pLEO160, p7.5, and mH5, which provided similar levels and dynamics of the reporter gene expression. These findings may be useful for developing multi-antigenic MVA-vectored vaccines.

modified vaccinia virus Ankara (MVA), genomic loci, poxvirus promoters, vector vaccine, p11, p13.5, pLEO160, p7.5, mH5



JMB-FOOTER RAS-JOURNALS